-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $265

Benzinga·07/06/2026 12:49:28
Listen to the news
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $240 to $265.